For individuals who are eligible for vaccination according to local allocation priorities, we recommend vaccination with one of the COVID-19 mRNA vaccines, BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) or mRNA 1273 (Moderna COVID-19 vaccine)
Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for controlling the COVID-19 pandemic. Various vaccines are becoming available in different countries; the COVID-19 mRNA vaccines BNT162b2 (Pfizer-BioNTech COVID-19 vaccine) and mRNA 1273 (Moderna COVID-19 vaccine) received emergency use authorization in the United States in December 2020 . Each is given as two intramuscular doses separated by a few weeks. In large placebo-controlled trials, these vaccine had 95 percent efficacy in preventing laboratory-confirmed symptomatic COVID-19 after the second dose . Local and systemic adverse effects (pain, fever, fatigue, headache) are common but usually nonsevere. Initial vaccine supplies are limited; in the United States, health care personnel and long-term care facility residents are prioritized for vaccination.
what is grade 1 b recommendation
|A Grade 1B recommendation is a strong recommendation, and applies to most patients. Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present.|
|A Grade 1 recommendation is a strong recommendation. It means that we believe that if you follow the recommendation, you will be doing more good than harm for most, if not all of your patients.|
|Grade B means that the best estimates of the critical benefits and risks come from randomized, controlled trials with important limitations (eg, inconsistent results, methodologic flaws, imprecise results, extrapolation from a different population or setting) or very strong evidence of some other form. Further research (if performed) is likely to have an impact on our confidence in the estimates of benefit and risk, and may change the estimates.|
1. Strong recommendation: Benefits clearly outweigh the risks and burdens (or vice versa) for most, if not all, patients
2. Weak recommendation: Benefits and risks closely balanced and/or uncertain
A. High-quality evidence: Consistent evidence from randomized trials, or overwhelming evidence of some other form
B. Moderate-quality evidence: Evidence from randomized trials with important limitations, or very strong evidence of some other form
C. Low-quality evidence: Evidence from observational studies, unsystematic clinical observations, or from randomized trials with serious flaws
For a complete description of our grading system, please see the UpToDate editorial policy.